Axon Enterprise, Inc. (NASDAQ:AXON) Stock Holdings Lifted by Ossiam

Ossiam grew its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 1,193.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 22,079 shares of the biotechnology company’s stock after acquiring an additional 20,372 shares during the period. Ossiam’s holdings in Axon Enterprise were worth $13,122,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AXON. Wilmington Savings Fund Society FSB purchased a new stake in shares of Axon Enterprise during the third quarter valued at $759,000. Tidal Investments LLC boosted its holdings in shares of Axon Enterprise by 13.8% in the third quarter. Tidal Investments LLC now owns 3,250 shares of the biotechnology company’s stock worth $1,299,000 after buying an additional 394 shares during the period. Denver PWM LLC increased its position in shares of Axon Enterprise by 69.7% in the third quarter. Denver PWM LLC now owns 414 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 170 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new stake in shares of Axon Enterprise during the third quarter valued at approximately $1,522,000. Finally, Brass Tax Wealth Management Inc. purchased a new stake in shares of Axon Enterprise in the 3rd quarter valued at approximately $240,000. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Trading Down 2.2 %

Shares of NASDAQ AXON opened at $559.53 on Friday. The stock has a market cap of $42.87 billion, a price-to-earnings ratio of 144.58, a PEG ratio of 5.17 and a beta of 1.13. The business has a 50 day simple moving average of $556.27 and a 200 day simple moving average of $565.34. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $715.99.

Analysts Set New Price Targets

Several equities analysts have weighed in on AXON shares. Needham & Company LLC reiterated a “buy” rating and set a $600.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 26th. TD Cowen initiated coverage on Axon Enterprise in a report on Wednesday, January 8th. They set a “buy” rating and a $700.00 price target on the stock. Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Finally, Craig Hallum downgraded Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $626.45.

Insiders Place Their Bets

In other Axon Enterprise news, Director Jeri Williams sold 307 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the transaction, the director now directly owns 1,627 shares in the company, valued at $899,275.44. This trade represents a 15.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.10% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.